1. Maron, BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287: 1308–1320.
2. Bos, JM, Towbin, JA, Ackerman, MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54: 201–211.
3. Ho, CY. Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation 2010; 122: 2430–2440.
4. McLeod, CJ, Bos, JM, Theis, JL, et al. Histologic characterization of hypertrophic cardiomyopathy with and without myofilament mutations. Am Heart J 2009; 158: 799–805.
5. Marian, AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000; 355: 58–60.
6. Ackerman, MJ, Priori, SG, Willems, S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 2011; 13: 1077–1109.
7. Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J, 2014; 35: 2733-2779.
8. Wang, L, Zuo, L, Hu, J, et al. Dual LQT1 and HCM phenotypes associated with tetrad heterozygous mutations in KCNQ1, MYH7, MYLK2, and TMEM70 genes in a three-generation Chinese family. Europace 2016; 18: 602–609.
9. Lang, RM, Badano, LP, Mor-Avi, V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1–39.e14.
10. Nagueh, SF, Appleton, CP, Gillebert, TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22: 107–133.
11. Diodato, D, Invernizzi, F, Lamantea, E, et al. Common and novel TMEM70 mutations in a cohort of Italian patients with mitochondrial encephalocardiomyopathy. JIMD Rep 2015; 15: 71–78.
12. Atay, Z, Bereket, A, Turan, S, et al. A novel homozygous TMEM70 mutation results in congenital cataract and neonatal mitochondrial encephalocardiomyopathy. Gene 2013; 515: 197–199.
13. Núñez, L, Gimeno-Blanes, JR, Rodríguez-García, MI, et al. Somatic MYH7, MYBPC3, TPM1, TNNT2, and TNNI3 mutations in sporadic hypertrophic cardiomyopathy. Circ J 2013; 77: 2358–2365.
14. Barsheshet, A, Goldenberg, I, O-Uchi, J, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation 2012; 125: 1988–1996.
15. Davis, JS, Hassanzadeh, S, Winitsky, S, et al. The overall pattern of cardiac contraction depends on a spatial gradient of myosin regulatory light chain phosphorylation. Cell 2001; 107: 631–641.
16. Carasso, S, Yang, H, Woo, A, et al. Systolic myocardial mechanics in hypertrophic cardiomyopathy: novel concepts and implications for clinical status. J Am Soc Echocardiogr 2008; 21: 675–683.
17. Kleijn, SA, Brouwer, WP, Aly, MF, et al. Comparison between three-dimensional speckle-tracking echocardiography and cardiac magnetic resonance imaging for quantification of left ventricular volumes and function. Eur Heart J Cardiovasc Imaging 2012; 13: 834–839.
18. Seo, Y, Ishizu, T, Enomoto, Y, et al. Validation of 3-dimensional speckle tracking imaging to quantify regional myocardial deformation. Circ Cardiovasc Imaging 2009; 2: 451–459.
19. Kansal, MM, Lester, SJ, Surapaneni, P, et al. Usefulness of two-dimensional and speckle tracking echocardiography in “Gray Zone” left ventricular hypertrophy to differentiate professional football player’s heart from hypertrophic cardiomyopathy. Am J Cardiol 2011; 108: 1322–1326.
20. Baccouche, H, Maunz, M, Beck, T, et al. Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography. Echocardiography 2012; 29: 668–677.
21. Wang, TT, Kwon, HS, Dai, G, et al. Resolving myoarchitectural disarray in the mouse ventricular wall with diffusion spectrum magnetic resonance imaging. Ann Biomed Eng 2010; 38: 2841–2850.
22. Urbano-Moral, JA, Rowin, EJ, Maron, MS, et al. Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2014; 7: 11–19.
23. Bing, W, Knott, A, Redwood, C, et al. Effect of hypertrophic cardiomyopathy mutations in human cardiac muscle alpha-tropomyosin (Asp175Asn and Glu180Gly) on the regulatory properties of human cardiac troponin determined by in vitro motility assay. J Mol Cell Cardiol 2000; 32: 1489–1498.